Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline

European Journal of Heart Failure

Volumn 21, Issue 3, 2019, Pages 386-388

  Januzzi, James ^a   Ferreira, João Pedro ^b   Böhm, Michael ^c   Kaul, Sanjay ^d   Wanner, Christoph ^e   Brueckmann, Martina ^f,g   Petrie, Mark C ^h   Ofstad, Anne Pernille ⁱ   Zeller, Cordula ^f   George, Jyothis ^f   Fitchett, David ^j   Zannad, Faiez ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITÉ DE LORRAINE   (France)

^c SAARLAND UNIVERSITY   (Germany)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ Boehringer Ingelheim Norway KS   (Norway)

^j ST MICHAEL'S HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; PLACEBO; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; CARDIOTONIC AGENT; GLUCOSIDE;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CONFIDENCE INTERVAL; HAZARD RATIO; HEART DEATH; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK REDUCTION; COMORBIDITY; DRUG EFFECT; HEMODYNAMICS; PATHOPHYSIOLOGY; PHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

BENZHYDRYL COMPOUNDS; CARDIOTONIC AGENTS; COMORBIDITY; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85061616029     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.1419     Document Type: Letter

References (7)

1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128.
2. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME® Trial Investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016;37:1526–1534.
3. Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, Woerle HJ, Hantel S, George JT, Johansen OE, Inzucchi SE; EMPA-REG OUTCOME® Trial Investigators. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J 2018;39:363–370.
4. Radholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation 2018;138:458–468.
5. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Ruff CT, Gause-Nilsson IA, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–357.
6. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RH, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31–39.
7. Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 2018;41:356–363.